- DKK155.51bn
- DKK180.62bn
- $3.72bn
Genmab scraps development of experimental cancer therapy
Brief: Genmab: Completion Of Tender Offer For Outstanding Common Shares Of Merus N.V.
Brief: Genmab Shares Encouraging Early-Stage Data On Epcoritamab For RT Patients
Brief: Genmab Announces Data From Multiple Clinical Trials
Brief: Genmab Presents Phase 3 Data from EPCORE FL-1 Trial
Europe Research Roundup: Auto1 Group, Roche Holding, Sanofi
Brief: Genmab Announces Pricing Of Private Offering Of Senior Secured Notes And Senior Unsecured Notes
Brief: Genmab Announces Proposed Private Offerings
Brief: Genmab Says Nine Months Revenue Increases 21% To $2,662 Million
Earnings Poll: Genmab A/S third quarter results due on November 6
Brief: Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan Achieved Anti-Tumor Activity In Heavily Pretreated Patients
Brief: Genmab: Darzalex Q3 Net Sales Total $3,672 Mln
TD Cowen raises Genmab's TP, calls $8 bln acquisition 'good strategic' deal
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Brief: Merus NV To Pay Genmab $240 Million Termination Fee Under Certain Conditions If Deal Falls Through - SEC Filing
Merus jumps on Genmab's $8 billion buyout deal
Live Markets: FTSE edges toward record as healthcare stocks surge
Genmab falls as it agrees to acquire Merus